ERBB2 and breast cancer: However, no association was observed between CDK2 with nuclear CDK4 co-expression and the outcome in endocrine-therapy-treated patients (Supplementary Figure S3C) or endocrine-therapy-naïve patients (Supplementary Figure S3D), or in triple-negative (Supplementary Figure S3E) or HER2-enriched BC (Supplementary Figure S3F).